(Q34224536)

31 July 2017

1 reference

title

Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans (English)

1 reference

31 July 2017

1 reference

Latts LM

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

American Journal of Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

110 Suppl 6A

1 reference

31 July 2017

page(s)

17S-23S

1 reference

Inadequate treatment with HMG-CoA reductase inhibitors by health care providers

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

A means to an end: an overview of a hyperlipidemia outcomes management program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy. An illustrative example focusing on the primary prevention of coronary heart disease in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

Maximizing the cost-effectiveness of lipid-lowering therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

Economic implications of lipid-lowering trials: current considerations in selecting a statin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900674-X

10.1016/S0002-9343(01)00674-X

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference